Prostate cancer

Prostate cancer is the most common cancer in men in the UK, with over 250,000 British men currently living with the disease. It is also the second most common cause of death due to cancer in England and Wales, surpassed only by lung cancer.

Despite its prevalence, obtaining a definitive diagnosis of prostate cancer can be challenging, and patients are currently required to attend a number of appointments before they receive their diagnosis.

The majority of prostate cancers in the UK are currently diagnosed from a transrectal ultrasound guided (TRUS) biopsy. Under the current clinic model, delays in waiting for a MRI scan appointment can result in delays for patients who need a TRUS biopsy procedure, and thus a delay to their diagnosis.

The MRI radiology team are working with the urology clinical team to enable MRI appointments to be offered to patients who need a TRUS biopsy within 2 days of their first visit to the urology clinic. This will be enabled by increasing MRI capacity through the introduction of early evening appointment slots from February 2016.

TOHETI is working with the clinical, radiology and pathology teams to measure and evaluate this shift in offering MRI appointments within 2 days of the one-stop clinic:

  • Collect and analyse data to understand the processes involved
  • Collect patient experience to assess if the new evening appointment slots helps to ease the anxiety of patients with prostate cancer symptoms
  • Inform design of a new on-the-day MRI service, which will become part of the urology one-stop clinic from Summer 2016.

Prostate cancer